Skip to site menu Skip to page content

Case Study: Immunomedics

By Modality Solutions

Immunomedics (www.immunomedics.com) is a clinical-stage biopharmaceutical company developing monoclonal antibody-based products for the targeted treatment of cancer.

Immunomedics’ corporate objective is to become a fully-integrated biopharmaceutical company and a leader in the field of Antibody-Drug Conjugates (ADC).

The US Food and Drug Administration (FDA) has granted fast-track designation for sacituzumab govitecan (IMMUNO-132).

Enter your details below to view the free white paper

By downloading this whitepaper, you acknowledge that GlobalData may share your information with our white paper partners/sponsors who may contact you directly with information on their products and services.

Visit our Privacy Policy for more information about our services, how GlobalData may use, process and share your personal data, including information on your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Related Content